Standout Papers

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (... 2023 2026 202456
  1. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2) (2023)
    Ohsang Kwon, Maryanne M. Senna et al. American Journal of Clinical Dermatology

Immediate Impact

21 standout
Sub-graph 1 of 10

Citing Papers

NF-κB in biology and targeted therapy: new insights and translational implications
2024 Standout
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
2024 Standout
3 intermediate papers

Works of Guanglei Yu being referenced

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
2023 Standout
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
2021

Author Peers

Author Last Decade Papers Cites
Guanglei Yu 153 15 28 123 73 30 266
A. E. Macbeth 136 21 45 162 27 22 238
Sonia Sofìa Ocampo‐Garza 95 10 53 149 41 31 311
Dmitri Wall 190 16 32 188 60 26 293
Ryokichi Irisawa 180 5 53 134 60 29 299
Youyu Sheng 219 9 21 149 34 25 316
Wei Jing Loo 17 2 40 154 67 25 293
Lena Möbus 16 29 11 152 8 21 286
Parviz Toossi 18 6 21 161 84 25 336
Sorina Dănescu 24 2 29 44 127 33 229
Dimitrios Sgouros 22 3 96 151 24 37 225

All Works

Loading papers...

Rankless by CCL
2026